Saturday, June 28, 2025 6/28/2025

Live Tumor Culture Core and Tissue Specific Culture System for Human Cancers

Award Number: R33CA214310
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 02/01/2018
PERIOD OF PERFORMANCE END DATE: 01/31/2024

Group Awards By:

View Award Description

Live Tumor Culture Core and Tissue Specific Culture System for Human Cancers - PROJECT SUMMARY Background: Many steps of cancer drug development involves the use of standard cancer cell lines (SCCL) which have been instrumental in the development of many targeted therapies; including Herceptin, Gleevac and Tamoxifen among others. However, establishing new CCL that mimic human disease is still challenging due to in vitro clonal selection and loss of the original tumor phenotype. In addition, the efficiency of creating new cell lines is very low. As a result, ~90% of ovarian and breast cancer research has been carried out in 5 CCL each 1, 2. These SCCL and leukemia cell lines do not fully represent the real-life diversity of human disease. Innovation: One of the persistent shortcomings of cell culture technology is the use of full serum, drugs and feeder layers that are partly responsible for the poor replication of the original tumor phenotype. In order to address these problems we developed a series of serum-free tissue specific culture (TSC) media that increases the efficiency of establishing new cell lines to > 50% and retains important tissue specific original tumor features. Preliminary data: We recently published the first application of the TSC technology for ovarian cancer (OvCa), describing 25 new OvCa cell lines that retain molecular, histologic and outcome features of the patient tumors. Objectives: Our long-term goal is to develop novel TSC media and methods to expand our technology to all tumor types and improve the methods to solve the stromal and normal cell overgrowth problem. Specific Aims: While we work on all tumor types, in this grant we focus on solid tumors (Breast, Ovary) and a liquid tumor (Leukemia) to illustrate that our system can be adapted to culture the full spectrum of tumor types. Aim 1) Characterization of new breast cancer cell lines: We formulated a new normal breast specific and breast cancer specific media, which we will use to establish matching normal and cancer cell lines. Aim 2) Characterization of new acute myeloid leukemia (AML) lines: We formulated a new serum-free medium customized for AML, which we will use to establish new AML cell lines. Aim 3) Culture of sub-optimal samples: Tissue samples with <10% tumor are difficult to culture due to stromal over-growth. We developed a method that suppress stroma to enable culture of sub-optimal tissue samples. Validation of Cancer-Relevant Biospecimen Science Technology: The genome, transcriptome and proteome of each cell line will be compared to the original patient tumor, existing cell lines and tumor datasets. Substantial Improvement and New Capabilities. Our TSC system can maintain cell lines without feeder layers, drugs, extracts, and suppresses the over-growth of stromal and normal cells. Transformative Potential. The biological relevance of SCCL is highly questionable. Hence, it is not surprising that drugs that are developed using SCCL frequently fail in the clinic. Our ability to provide biologically relevant BrCa, OvCa, and AML cell lines can have a transformative effect on cancer drug development.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$3,923 )
2024	2020	WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY	575 LEXINGTON AVE FL 9	NEW YORK	NY	10022	NEW YORK	USA	Cancer Biology Research	000	3	6/11/2024	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	-$3,923
														Subtotal = -$3,923

Issue Date FY: 2023 ( Subtotal = $0 )
2023	2020	WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY	1300 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Biology Research	000	3	9/20/2023	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
														Subtotal = $0

Issue Date FY: 2022 ( Subtotal = $0 )
2022	2020	WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY	1300 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Biology Research	000	3	4/25/2022	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
														Subtotal = $0

Issue Date FY: 2021 ( Subtotal = $0 )
2021	2020	WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY	1300 YORK AVE	NEW YORK	NY	10065	NEW YORK	USA	Cancer Biology Research	002	3	12/1/2020	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$201,584
2021	2019	UNIVERSITY OF MIAMI	1600 NW 10 AVE	MIAMI	FL	33136	MIAMI-DADE	USA	Cancer Biology Research	000	2	12/1/2020	NON-COMPETING CONTINUATION	-$157,371
2021	2019	UNIVERSITY OF MIAMI	1600 NW 10 AVE	MIAMI	FL	33136	MIAMI-DADE	USA	NIH Office of Research on Women's Health	001	2	12/1/2020	SUPPLEMENT FOR EXPANSION	-$44,213
														Subtotal = $0

Issue Date FY: 2020 ( Subtotal = $539,092 )
2020	2020	WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY	407 E 61ST ST RM 106 1ST FL	NEW YORK	NY	10065	NEW YORK	USA	Cancer Biology Research	002	3	9/11/2020	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$0
2020	2020	WEILL MEDICAL COLLEGE OF CORNELL UNIVERSITY	407 E 61ST ST RM 106 1ST FL	NEW YORK	NY	10065	NEW YORK	USA	Cancer Biology Research	001	3	8/17/2020	CHANGE OF GRANTEE / TRAINING INSTITUTION / AWARDING INSTITUTION	$539,092
2020	2019	UNIVERSITY OF MIAMI	1600 NW 10 AVE	MIAMI	FL	33136	MIAMI-DADE	USA	Cancer Biology Research	000	2	8/14/2020	NON-COMPETING CONTINUATION	$0
														Subtotal = $539,092

Issue Date FY: 2019 ( Subtotal = $414,961 )
2019	2019	UNIVERSITY OF MIAMI	1600 NW 10 AVE	MIAMI	FL	33136	MIAMI-DADE	USA	Cancer Biology Research	000	2	1/31/2019	NON-COMPETING CONTINUATION	$370,748
2019	2019	UNIVERSITY OF MIAMI	1600 NW 10 AVE	MIAMI	FL	33136	MIAMI-DADE	USA	NIH Office of Research on Women's Health	001	2	9/13/2019	SUPPLEMENT FOR EXPANSION	$44,213
														Subtotal = $414,961

Issue Date FY: 2018 ( Subtotal = $382,215 )
2018	2018	UNIVERSITY OF MIAMI	1600 NW 10 AVE	MIAMI	FL	33136	MIAMI-DADE	USA	Cancer Biology Research	000	1	2/7/2018	NEW	$382,215
														Subtotal = $382,215

Grand Total All Awards = $1,332,345

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Live Tumor Culture Core and Tissue Specific Culture System for Human Cancers

Award Number: R33CA214310

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 02/01/2018

PERIOD OF PERFORMANCE END DATE: 01/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer